Structure-Based Drug Design for Epigenetic Targets Course
- 1. Structure-Based Drug Design for Epigenetic Targets ***** A Short Course Announcement ***** with Johnathan R. Whetstine, Ph.D., Assistant Professor of Medicine, Harvard Medical School & Philip Fallon, Ph.D., Senior Medicinal Chemist, Domainex Ltd. June 19, 2013 – The Revere Hotel – Boston, MA Epigenetic processes are the focus of intense interest, and the families of proteins that mediate epigenetic signalling are a highly promising source of new drug targets. Tackling this emerging field of novel drug targets is not without its challenges. This workshop will review the contribution that structural biology has made to the discovery of small molecule modulators. Structural information can be invaluable in determining the druggability of potential targets, and in enabling more efficient identification of hit molecules. Structural information can also guide the design of compounds with improved affinity for the target, or selectivity versus other targets. This introductory course on drug design for epigenetic targets will focus especially on emerging targets such as bromodomain (readers), methyltransferase (writers) and lysine demethylase (erasers). This course will be held from 9:00 am – 12:00 pm prior to the start of CHI’s Structure- Based Drug Design conference (June 19-21). WAYS TO REGISTER: Online: https://chidb.com/register/2013/sbd/reg.asp Call: 781-972-5400 Email: reg@healthtech.com http://www.healthtech.com/sbd